ARVN - Arvinas Inc Stock Price, Fair Value and News

$12.68+1.02 (+8.75%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ARVN Price Action

Last 7 days

2.1%

Last 30 days

30.5%

Last 90 days

66.6%

Trailing 12 Months

-47.6%

ARVN RSI Chart

ARVN Valuation

Market Cap

814.4M

Price/Earnings (Trailing)

-13.92

Price/Sales (Trailing)

2.61

EV/EBITDA

-12.91

Price/Free Cashflow

-2.47

ARVN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ARVN Fundamentals

ARVN Revenue

Revenue (TTM)

312.3M

Rev. Growth (Yr)

-59.08%

Rev. Growth (Qtr)

87.05%

ARVN Earnings

Earnings (TTM)

-58.5M

Earnings Growth (Yr)

28.66%

Earnings Growth (Qtr)

42.65%

ARVN Profitability

EBT Margin

-18.78%

Return on Equity

-10.36%

Return on Assets

-6.93%

Free Cashflow Yield

-40.46%

ARVN Investor Care

Buy Backs (1Y)

6.53%

Diluted EPS (TTM)

-0.81

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	426.9M	372.8M	312.3M	0
2024	124.7M	170.9M	217.2M	263.4M
2023	137.3M	158.1M	159.4M	78.5M
2022	74.5M	102.8M	126.8M	131.3M
2021	25.2M	24.9M	26.6M	53.5M
2020	45.2M	46.9M	24.5M	25.9M
2019	14.2M	14.8M	41.5M	43.0M
2018	10.0M	11.7M	13.5M	14.3M
2017	0	0	0	7.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

CEO	Dr. John G. Houston Ph.D.
WEBSITE	arvinas.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	415

Arvinas Inc Frequently Asked Questions

What is the ticker symbol for Arvinas Inc? What does ARVN stand for in stocks?

ARVN is the stock ticker symbol of Arvinas Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arvinas Inc (ARVN)?

As of Wed Dec 03 2025, market cap of Arvinas Inc is 814.36 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARVN stock?

You can check ARVN's fair value in chart for subscribers.

Is Arvinas Inc a good stock to buy?

The fair value guage provides a quick view whether ARVN is over valued or under valued. Whether Arvinas Inc is cheap or expensive depends on the assumptions which impact Arvinas Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARVN.

What is Arvinas Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, ARVN's PE ratio (Price to Earnings) is -13.92 and Price to Sales (PS) ratio is 2.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARVN PE ratio will change depending on the future growth rate expectations of investors.